Replies to post #12169 on Imaging Diagnostic Systems (fka IMDS)

[~ Blue ~]

Bio Med. Prof. HUABEI JIANG -IMDS Scientific Advisory Board Member, UNIVERSITY OF FLORIDA

J. Crayton Pruitt Family Professor
Ph.D., 1988, University of Electronic Science
and Technology of China
Ph.D., 1995, Dartmouth College


DIFFUSE OPTICAL TOMOGRAPHY OF BREAST CANCER

Breast cancer has been one of the leading causes of
death for women in the United States. Yet, the best
way of combating the increased incidence of breast
cancer is early detection. Therefore, there is a critical need to investigate breast cancer detection methods that could serve
either a complementary or competitive role with respect to
conventional x-ray mammography, which has unacceptable
false negative rate for patients with radiodense breast tissues.

The fundamental hypothesis of our research is that spatially
and spectrally resolved NIR diffuse optical tomography (DOT) (REMEMBER FDA ACCEPT IMDS's CTLM AS A DOT DEVICE)
approaches offer unparallel opportunity to access the molecular
and cellular signatures in breast tissue through endogenous
contrast mechanisms. To clinically evaluate optical tomography
based on absorption chromophores and scattering parameters,
three clinical prototype imagers have been constructed.
We have also developed a new contrast mechanism for NIR
tomography based on refractive index/phase contrast: the initial
clinical results show that the addition of refractive index
can significantly improve our ability for distinguishing between
malignant and benign breast lesions.

page 13

http://www.bme.ufl.edu/bmebrochure.pdf